⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550864 | 1.00 | — | — | |
| SCHEMBL13563 | 1.00 | — | — | |
| SCHEMBL28281550 | 0.95 | OR51E2 (0.35) | — | |
| SCHEMBL440539 | 0.92 | — | — | |
| SCHEMBL540667 | 0.90 | — | — | |
| SCHEMBL28580896 | 0.90 | CA1 (0.39) | — | |
| SCHEMBL4198 | 0.82 | — | — | |
| SCHEMBL969300 | 0.82 | — | — | |
| SCHEMBL80643 | 0.82 | — | — | |
| SCHEMBL4621927 | 0.82 | FABP6 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172222-A1 | Oxazolidinones for the Treatment of Inflammatory Conditions of the Gastrointestinal Tract | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2296649-A1 | OXAZOLIDINONES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE GASTROINTESTINAL TRACT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20110003804-A1 | Oxazolidinones For the Treatment and/or Prophylaxis of Heart Failure | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
| EP-2229173-A1 | OXAZOLIDINONES FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEART FAILURE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100144728-A1 | Oxazolidinone For The Treatment And Prophylaxis Of Pulmonary Hypertension | BAYER SCHERING PHARMA AG (DE) | 2010-06-10 | — | — | US | disclosed |
| CN-101711155-A | Oxazolidinones for the treatment and prevention of pulmonary hypertension | BAYER HEALTHCARE AG | 2010-05-19 | — | — | CN | disclosed |
| WO-2010000404-A1 | OXAZOLIDINONES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE GASTROINTESTINAL TRACT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-07 | — | — | WO | disclosed |
| EP-2140866-A1 | Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-01-06 | — | — | EP | disclosed |
| EP-2138178-A1 | Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009156082-A1 | OXAZOLIDINONES FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009074249-A1 | OXAZOLIDINONES FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEART FAILURE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008155035-A2 | OXAZOLIDINONES FOR THE TREATMENT AND PROPHYLAXIS OF SEPSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |